IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQVIA Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$262.27|
|52 Week High||US$146.00|
|52 Week Low||US$265.34|
|1 Month Change||2.11%|
|3 Month Change||6.90%|
|1 Year Change||77.13%|
|3 Year Change||100.56%|
|5 Year Change||231.74%|
|Change since IPO||522.82%|
Recent News & Updates
|IQV||US Life Sciences||US Market|
Return vs Industry: IQV exceeded the US Life Sciences industry which returned 58.3% over the past year.
Return vs Market: IQV exceeded the US Market which returned 36.2% over the past year.
Stable Share Price: IQV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: IQV's weekly volatility (2%) has been stable over the past year.
About the Company
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Fundamentals Summary
|IQV fundamental statistics|
Is IQV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQV income statement (TTM)|
|Cost of Revenue||US$8.59b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.17|
|Net Profit Margin||4.69%|
How did IQV perform over the long term?See historical performance and comparison
Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IQV ($262.27) is trading below our estimate of fair value ($320.1)
Significantly Below Fair Value: IQV is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: IQV is poor value based on its PE Ratio (82.8x) compared to the US Life Sciences industry average (52.2x).
PE vs Market: IQV is poor value based on its PE Ratio (82.8x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: IQV is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: IQV is overvalued based on its PB Ratio (8.7x) compared to the US Life Sciences industry average (6.1x).
How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQV's forecast earnings growth (26% per year) is above the savings rate (2%).
Earnings vs Market: IQV's earnings (26% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IQV's revenue (9.4% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: IQV's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (24.2%)
How has IQVIA Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQV has high quality earnings.
Growing Profit Margin: IQV's current net profit margins (4.7%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: IQV's earnings have declined by 6.1% per year over the past 5 years.
Accelerating Growth: IQV's earnings growth over the past year (359.8%) exceeds its 5-year average (-6.1% per year).
Earnings vs Industry: IQV earnings growth over the past year (359.8%) exceeded the Life Sciences industry 56.9%.
Return on Equity
High ROE: IQV's Return on Equity (10.9%) is considered low.
How is IQVIA Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IQV's short term assets ($5.1B) exceed its short term liabilities ($4.8B).
Long Term Liabilities: IQV's short term assets ($5.1B) do not cover its long term liabilities ($13.4B).
Debt to Equity History and Analysis
Debt Level: IQV's debt to equity ratio (214%) is considered high.
Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IQV's debt is well covered by operating cash flow (22.1%).
Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (3x coverage).
What is IQVIA Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IQV is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ari Bousbib (60 yo)
Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of...
CEO Compensation Analysis
Compensation vs Market: Ari's total compensation ($USD25.58M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Ari's compensation has been consistent with company performance over the past year.
Experienced Management: IQV's management team is considered experienced (4.9 years average tenure).
Experienced Board: IQV's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IQV insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IQVIA Holdings Inc.'s employee growth, exchange listings and data sources
- Name: IQVIA Holdings Inc.
- Ticker: IQV
- Exchange: NYSE
- Founded: 1982
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$49.771b
- Shares outstanding: 191.61m
- Website: https://www.iqvia.com
Number of Employees
- IQVIA Holdings Inc.
- 83 Wooster Heights Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:06|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.